Treatment of pediatric hodgkin Lymphoma

Current Treatment Options in Oncology

Volumn 9, Issue 1, 2008, Pages 81-94

  Olson, Michael R ^a   Donaldson, Sarah S ^a  

^a STANFORD CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE;

ANEMIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CARDIOMYOPATHY; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG WITHDRAWAL; HODGKIN DISEASE; HUMAN; IMAGING; LEUKEMIA; LUNG DISEASE; MALE INFERTILITY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; THROMBOCYTOPENIA; TREATMENT RESPONSE; REVIEW;

CHILD; COMBINED MODALITY THERAPY; HODGKIN DISEASE; HUMANS;

EID: 47049091227     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-008-0058-0     Document Type: Article

References (43)

1. Bennett MH, MacLennan KA, Vaughan Hudson G, Vaughan Hudson B: Non-Hodgkin's lymphoma arising in patients treated for Hodgkin's disease in the BNLI: A 20-year experience. British National Lymphoma Investigation. Ann Oncol 1991, 2(Suppl 2):83-92
2. Karayalcin G, Behm FG, Gieser PW, et al.: Lymphocyte predominant Hodgkin disease: Clinico-pathologic features and results of treatment - the Pediatric Oncology Group experience. Med Pediatr Oncol 1997, 29(6):519-525
3. Pellegrino B, Terrier-Lacombe MJ, Oberlin O, et al.: Lymphocyte-predominant Hodgkin's lymphoma in children: Therapeutic abstention after initial lymph node resection - a Study of the French Society of Pediatric Oncology. J Clin Oncol 2003, 21(15):2948-2952
4. Mauz-Korholz C, Gorde-Grosjean S, Hasenclever D, et al.: Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer 2007, 110(1):179-185
5. Donaldson SS, Hudson MM, Lamborn KR, et al.: VAMP and low-dose, involved-field radiation for children and adolescents with faorable, early-stage Hodgkin's disease: Results of a prospective clinical trial. J Clin Oncol 2002, 20(14):3081-3087
6. Donaldson SS, Link MP, Weinstein HJ, et al.: Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease. J Clin Oncol 2007, 25(3):332-337 Final results of our own response-adapted trial in favorable stage Hodgkin lymphoma
7. Dorffel W, Luders H, Ruhl U, et al.: Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: Analysis and outlook. Klin Padiatr 2003, 215(3):139-145 One of the best examples of a large, multicenter trial utilizing a modern response-adapted approach to the treatment of all stages of pediatric Hodgkin lymphoma
8. Ruhl U, Albrecht M, Dieckmann K, et al.: Response-adapted radiotherapy in the treatment of pediatric Hodgkin's disease: An interim report at 5 years of the German GPOH-HD 95 trial. Int J Radiat Oncol Biol Phys 2001, 51(5):1209-1218
9. Ruhl U, Albrecht MR, Lueders H, et al.: Abstract at ASTRO, 46th annual meeting: The German multinational GPOH-HD 95 trial: Treatment results and analysis of failures in pediatric Hodgkins disease using combination chemotherapy with and without radiation. Int J Radiat Oncol Biol Phys 2004, 60:S131
10. Landman-Parker J, Pacquement H, Leblanc T, et al.: Localized childhood Hodgkin's disease: Response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol 2000, 18(7):1500-1507. An excellent example of response-adapted therapy applied to early stage Hodgkin lymphoma
11. Willman KY, Cox RS, Donaldson SS: Radiation induced height impairment in pediatric Hodgkin's disease. Int J Radiat Oncol Biol Phys 1994, 28(1):85-92
12. Tebbi CK, Mendenhall N, London WB, et al.: Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: A Pediatric Oncology Group (POG) study. Pediatr Blood Cancer 2006, 46(2):198-202
13. Chow LM, Nathan PC, Hodgson DC, et al.: Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation. J Clin Oncol 2006, 24(36):5735-5741
14. Hancock SL, Hoppe RT: Long-term complications of treatment and causes of mortality after Hodgkin's disease. Semin Radiat Oncol 1996, 6(3):225-242
15. Hancock SL, Donaldson SS, Hoppe RT: Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol 1993, 11(7):1208-1215
16. Bhatia S, Robison LL, Oberlin O, et al.: Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996, 334(12):745-751. An excellent overview of late effects resulting from treatment for Hodgkin lymphoma
17. Bhatia S, Meadows AT, Robison LL: Second cancers after pediatric Hodgkin's disease. J Clin Oncol 1998, 16(7):2570-2572
18. Lin HM, Teitell MA: Second malignancy after treatment of pediatric Hodgkin disease. J Pediatr Hematol Oncol 2005, 27(1):28-36
19. Wolden SL, Lamborn KR, Cleary SF, et al.: Second cancers following pediatric Hodgkin's disease. J Clin Oncol 1998, 16(2):536-544
20. Hudson MM, Poquette CA, Lee J, et al.: Increased mortality after successful treatment for Hodgkin's disease. J Clin Oncol 1998, 16(11):3592-3600
21. KungAFH, Schwartz CL, Ferree CR, et al.: POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with stages I, IIA, IIIA1 Hodgkin disease: A report from the Children's Oncology Group. J Pediatr Hematol Oncol 2006, 28(6):362-368
22. NnachmanJB, Sposto P., Herzog, et al.: Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002, 20(18):3765-3771. An excellent trial highlighting the central debate in treatment of pediatric Hodgkin lymphoma-whether or not radiotherapy should be employed
23. Glick JH, Young ML, Harrington D, et al.: MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: The 8-year results of the intergroup trial. J Clin Oncol 1998, 16(1):19-26. A study highlighting the trade-off between the use of radiation therapy and the decreased event-free survival of its omission
24. Armata J, Balwierz W, Moryl-Bujakowska A, et al.: Childhood stage IV Hodgkin disease: Therapeutic results of the Polish pediatric leukemia/ lymphoma study group. Med Pediatr Oncol 1999, 33(4):382-387
25. Hudson MM, Greenwald C, Thompson E, et al.: Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin's disease. J Clin Oncol 1993, 11(1):100-108
26. Hudson MM, Krasin M, Link MP, et al.: Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease. J Clin Oncol 2004, 22(22):4541-4550
27. Friedmann AM, Hudson MM, Weinstein HJ, et al.: Treatment of unfavorable childhood Hodgkin's disease with VEPA and low-dose, involved-field radiation. J Clin Oncol 2002, 20(14):3088-3094
28. Weiner MA, Leventhal B, Brecher ML, et al.: Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: A Pediatric Oncology Group study. J Clin Oncol 1997, 15(8):2769-2779
29. Fryer CJ, Hutchinson RJ, Krailo M, et al.: Efficacy and toxicity of 12 courses of ABVD chemotherapy followed by low-dose regional radiation in advanced Hodgkin's disease in children: A report from the Children's Cancer Study Group. J Clin Oncol 1990. 8(12):1971-1980
30. Halperin, EC:THodgkin's disease: technical aspects. in Pediatric Radiation Oncology Congress. 2007, Barcelona, Spain. www.intpros.org
31. Goldie JH, AJ Coldman, GA Gudauskas: Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep, 1982. 66(3):439-449
32. Diehl V, J Franklin, D Hasenclever, et al.: BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ ABVD in patients with advanced-stage Hodgkin's lymphoma: Interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol, 1998. 16(12):3810-3821
33. Diehl V, J Franklin, M Pfreundschuh, et al.: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med, 2003 348(24):2386-2395
34. Kelly KM, RJ Hutchinson, R Sposto, et al.: Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: Preliminary results from the Children's Cancer Group Study CCG-59704. Ann Oncol, 2002. 13 Suppl 1:107-111
35. Aversa SM, L Salvagno, M Soraru, et al.: Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin's disease. Acta Haematol, 2004. 112(3):141-147
36. Horning SJ, RT Hoppe, S Breslin, et al.: Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: Mature results of a prospective clinical trial. J Clin Oncol 2002. 20(3):630-637
37. Hudson MM, SS Donaldson: Treatment of pediatric Hodgkin's lymphoma. Semin Hematol 1999. 36(3):313-323
38. Lieskovsky YE, SS Donaldson, MA Torres, et al. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: Results and prognostic indices. J Clin Oncol, 2004. 22(22):4532-4540
39. Oberlin O, G Leverger, H Pacquement, et al., Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: The experience of the French Society of Pediatric Oncology. J Clin Oncol, 1992. 10(10):1602-1608
40. Vecchi V, S Pileri, R Burnelli, et al. Treatment of pediatric Hodgkin disease tailored to stage, mediastinal mass, and age. An Italian (AIEOP) multicenter study on 215 patients. Cancer, 1993. 72(6):2049-2057
41. Ekert H, T Fok, L Dalla-Pozza, et al. A pilot study of EVAP/ABV chemotherapy in 25 newly diagnosed children with Hodgkin's disease. Br J Cancer, 1993. 67(1):159-162
42. van den Berg H, J Zsiros, H Behrendt, Treatment of childhood Hodgkin's disease without radiotherapy. Ann Oncol, 1997 8 (Suppl 1):15-17
43. Lobo-Sanahuja F, I Garcia, JC Barrantes, et al., Pediatric Hodgkin's disease in Costa Rica: Twelve years' experience of primary treatment by chemotherapy alone, without staging laparotomy. Med Pediatr Oncol, 1994. 22(6):398-403